GlaxoSmithKline Pharmaceuticals Ltd. - Research Center
500660 GLAXO Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 24 | Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | |
|---|---|---|---|---|---|
| Sales | 1,811.05 | 1,691.40 | 1,635.07 | 1,599.90 | 1,764.99 |
| Operating profit | 548.37 | 427.83 | 404.85 | 370.08 | 425.08 |
| Interest | 0.64 | 0.71 | 1.07 | 0.85 | 1.14 |
| Gross profit | 615.77 | 492.39 | 453.73 | 398.67 | 470.72 |
| EPS (Rs) | 25.40 | 20.43 | 18.43 | 80.72 | 19.07 |
Half yearly
results in details
| Sep ' 24 | Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | |
|---|---|---|---|---|---|
| Other income | 68.04 | 65.27 | 49.95 | 29.44 | 46.78 |
| Stock adjustment | 9.36 | -34.67 | -116.86 | 7.88 | 4.25 |
| Raw material | 270.58 | 225.18 | 255.53 | 240.13 | 312.25 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 301.99 | 310.21 | 293.16 | 282.43 | 327.80 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 680.75 | 762.85 | 798.39 | 699.38 | 695.61 |
| Provisions made | - | - | - | - | - |
| Depreciation | 33.27 | 34.47 | 32.18 | 33.22 | 35.31 |
| Taxation | 156.85 | 129.10 | 112.36 | 295.34 | 112.36 |
| Net profit / loss | 430.34 | 346.12 | 312.24 | 1,367.47 | 323.05 |
| Extra ordinary item | 4.69 | 17.30 | 3.05 | 1,297.36 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 30.28 | 25.29 | 24.76 | 23.13 | 24.08 |
| GPM (%) | 32.77 | 28.03 | 26.93 | 24.47 | 25.98 |
| NPM (%) | 22.90 | 19.70 | 18.53 | 83.93 | 17.83 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis